Literature DB >> 18413334

Surrogate endpoints: wishful thinking or reality?

Tomasz Burzykowski.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18413334     DOI： 10.1177/0962280207081866

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN： 0962-2802            Impact factor:   3.021


× No keyword cloud information.
  3 in total

1.  Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Authors:  S J Hotte; G A Bjarnason; D Y C Heng; M A S Jewett; A Kapoor; C Kollmannsberger; J Maroun; L A Mayhew; S North; M N Reaume; J D Ruether; D Soulieres; P M Venner; E W Winquist; L Wood; J H E Yong; F Saad
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

Review 2.  Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors:  Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.

Authors:  Silvy Laporte; Pierre Squifflet; Noémie Baroux; Frank Fossella; Vassilis Georgoulias; Jean-Louis Pujol; Jean-Yves Douillard; Shinzohy Kudoh; Jean-Pierre Pignon; Emmanuel Quinaux; Marc Buyse
Journal:  BMJ Open       Date:  2013-03-13       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.